Drug
608
608 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting1
Not yet recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
recruiting133%
not_yet_recruiting133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
not_yet_recruitingphase_3
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT07349329
recruitingphase_2
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT06222671
unknownphase_1
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
NCT04367441
Clinical Trials (3)
Showing 3 of 3 trials
NCT07349329Phase 3
A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT06222671Phase 2
A Study to Evaluate 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA)
NCT04367441Phase 1
Randomized, Double Blinded, Placebo Controlled, Single Dose Escalation Study of 608 in Healthy Subjects
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3